Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP000329

Drug Information
SynonymsKetotifeno; Ketotiphene; AC1L1GSZ; UNII-X49220T18G; NCGC00015580-09; 116655-74-4; Ketotifene [INN-French]; BRN 3983897; HMS2090F16; BAS 00444483; Prestwick1_000371; STK048448; Ketotifen (INN); NCGC00022572-05; AKOS000541268; Ketotifene; 4-(1-Methyl-piperidin-4-ylidene)-4,9-dihydro-1-thia-benzo[f]azulen-10-one; HC 20-511; BRD-K28936863-051-05-8; Ketotifene fumarate; L000753; Tocris-0784; NCGC00015580-03; Spectrum3_001382; Oprea1_553550; CHEBI:112957; SPBio_001275; BSPBio_002964; 4-(1-Methyl-4-piperidylidene)-9-hydrobenzo[a]thiopheno[3,2-d][7]annulen-10-one; 10H-Benzo[4,5]cyclohepta[1,2-b]thiophen-10-one, 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-, (2E)-2-butenedioate (1:1); KBio2_006042; CAS-34580-14-8; 10H-Benzo(4,5)cyclohepta(1,2-b)thiophen-10-one, 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-; BSPBio_000521; HSDB 7283; EINECS 252-099-7; BIDD:GT0509; NCGC00022572-04; 4,9-Dihydro-4-(1-methyl-4-piperidylidene)-10H-benzo(4,5)-cyclohepta(1,2-b)thiophen-10-one; Lopac-K-2628; Ketotiphen; Lopac0_000706; Ketotifenum; NINDS_000111; Spectrum2_001198; STOCK1S-14132; AC-15945; 4,9-Dihydro-4-(1-methyl-4-piperidinylidene)-10H-benzo(4,5)cyclohepta(1,2-b)thiophen-10-one; 10H-Benzo[4,5]cyclohepta[1,2-b]thiophen-10-one, 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-; D08105; KBioSS_000906; C19H19NOS; LS-33820; Prestwick2_000371; ketotifen; Ketotifeno [INN-Spanish]; KBioGR_001289; NCGC00015580-02; IDI1_000111; KBio2_003474; CHEMBL534; Spectrum4_000805; Ketotifenum [INN-Latin]; CID3827; Spectrum_000426; Prestwick3_000371; Alaway (TN); Ketotifin; SPBio_002442; Oprea1_335550; 34580-13-7; KBio3_002184; BPBio1_000575; Prestwick0_000371; 4-(1-methylpiperidin-4-ylidene)-4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one; KBio2_000906; Spectrum5_001395; NCGC00015580-01; AB00053575; DivK1c_000111; KBio1_000111; MolPort-001-933-278; Ketotifen [INN:BAN]; Zaditor; DB00920; NCGC00022572-02    
Trade NameZaditor; Alaway    
CompanyNorvatis Phamaceuticals Corporation    
IndicationAllergic conjunctivitisApproved    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Therapeutic ClassAnti-Allergic Agents    
CAS NumberCAS 34580-14-8
PubChem Compound IDCID 3827.    
PubChem Substance IDSID 178305.    
SuperDrug ATC IDR06AX17;    
SuperDrug CAS ID034580137;    
TargetHistamine H1 receptorAntagonist[2][3]
Ref 1Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20. To Reference
Ref 2Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79. Epub 2008 Apr 29. To Reference
Ref 3Influence of chronic treatment with H1 receptor antagonists on the anticonvulsant activity of antiepileptic drugs. Pol J Pharmacol. 2001 Jan-Feb;53(1):93-6. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543